BioSpace News Archive

mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce the appointment of Jurgen Van Broeck as Chief Executive Officer.

Dyno Therapeutics announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that Jaguar family companies Napo Pharmaceuticals (“Napo”) and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar’s novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (SBS) with intestinal failure in adults.

The global epilepsy drugs market size reached a value of USD 9.50 billion in 2023 and is projected to grow to USD 15.16 billion by 2032, indicating at a CAGR of 5.1% for the period from 2024 to 2032.

The global pharmaceutical excipients market size was accounted for USD 8.37 billion in 2023 and it is projected to increase over USD 14.72 billion by 2033 with a CAGR of 5.81% from 2024 to 2033.

According to recent study by nova one advisor, the U.S. generic drugs market size is projected to surpass around USD 188.44 billion by 2033 from USD 133.59 billion in 2023 and is expanding at a CAGR of 3.5% between 2024 to 2033.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.

According to recent study by Nova One Advisor, the U.S. pharmaceutical filtration market size was valued at USD 4.85 billion in 2023 and is poised to exceed USD 8.39 billion by 2033, expanding at a CAGR of 5.63% between 2024 and 2033.

The global clinical trials support service market was valued at US$ 25.2 billion in 2023 and is projected to surpass US$ 47.1 billion by 2032, growing at a CAGR of 7.22% during the forecast period from 2024 to 2032.

Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting.